Advanced squamous cell cancers of the head and neck have traditionally been associated with high rates of morbidity and mortality. Advances in management have improved outcomes for most of these patients.
Methods
The author reviews the historical progress in management of these difficult tumors and adds his own wide experience to describe and evaluate newer approaches to management.
Results
Over the last 10 years, overall survival rates for patients with head and neck cancers have improved as has quality of life. New standards of care have been defined for patients with nasopharyngeal cancer and for those with advanced unresectable disease. Organ preservation is more commonly achieved.
Conclusions
Newer targeted therapies are likely to add to the progress that has already been achieved in the multimodality management of patients with head and neck cancers.
References
1.
Al-SarrafM.. Head and neck cancer: chemotherapy concepts.Semin Oncol.1988; 15: 70–85.
2.
Al-SarrafM.. Head and neck cancer: present status and future prospects of adjuvant chemotherapy.Cancer Invest.1995; 13: 41–53.
3.
RiesL.A.G., WingoP.A., MillerD.S.. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer.Cancer.2000; 88: 2398–2424.
4.
ManamR., Al-SarrafM.. Head and neck cancer. In: GiacconeG., SchilskyR., SondelP., eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 20.Amsterdam, Netherlands: Elsevier Science BV;2002: 1–16.
5.
SchrijversD., VermorkenJ.B.. Role of taxoids in head and neck cancer.Oncologist.2000; 5: 199–208.
6.
GlissonB.S.. The role of docetaxel in the management of squamous cell cancer of the head and neck.Oncology (Huntingt).2002; 16: 83–87.
7.
MurphyB., LiY., CellaD.. Phase III study comparing cisplatin (C) and 5-fluorouracil (F) versus cisplatin and paclitaxel (T) in metastatic/recurrent head and neck cancer (MHNC).Proc Annu Meet Am Soc Clin Oncol.2001; 20: 894. Abstract.
8.
CruzJ.J., FonescaE., Garcia-GomezJ.. Randomized phase II, multicenter trial of induction chemotherapy in patients with locally advanced head and neck carcinoma (LA-HNC). Docetaxel plus cisplatin (DP) versus cisplatin and 5-FU (PF): interim results.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 920. Abstract.
9.
PosnerM.R., GlissonB., FrenetteG.. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.J Clin Oncol.2001; 19: 1096–1104.
10.
VokesE.E., KiesM.S., HarafD.J.. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.J Clin Oncol.2000; 18: 1652–1661.
11.
ArgirisA.. Update on chemoradiotherapy for head and neck cancer.Curr Opin Oncol.2002; 14: 323–329.
12.
HaselowR.E., WarshawM.G., OkenM.M.. Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. In: FeeW.E., GoepfertH., JohnsM.E.., eds. Head and Neck Cancer.Toronto: BC Decker;1990: 279–281.
13.
JeremicB., ShibamotoY., StanisavljevicB.. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial.Radiother Oncol.1997; 43: 29–37.
14.
TsuchiyaK., NishiokaT., ShiratoH.. A randomized trial of concomitant chemoradiotherapy for head-and-neck cancers: cis-platin (CDDP) vs. carboplatin (CBDCA).Int J Radiat Oncol Biol Phys.2001; 51(suppl 1): 337. Abstract 2215.
15.
BernierJ., DomengeC., EschwegeF.. Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931.Int J Radiat Oncol Biol Phys.2001; 51(suppl 1): plenary 1.
16.
PignonJ.P., BourhisJ., DomengeC.. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data.Lancet.2000; 355: 949–955.
17.
BrowmanG.P., HodsonD.I., MackenzieR.J.. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis.Head Neck.2001; 23: 579–589.
18.
MerlanoM., BenassoM., CorvoR.. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.J Natl Cancer Inst.1996; 88: 583–589.
19.
BrizelD.M., AlbersM.E., FisherS.R.. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.N Engl J Med.1998; 338: 1798–1804.
20.
WendtT.G., GrabenbauerG.G., RodelC.M.. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.J Clin Oncol.1998; 16: 1318–1324.
21.
CalaisG., AlfonsiM., BardetE.. Randomized trial of radiation versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.J Natl Cancer Inst.1999; 91: 2081–2086.
22.
JeremicB., ShibamotoY., MilicicB.. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.J Clin Oncol.2000; 18: 1458–1464.
23.
AdelsteinD.J., AdamsG.L., LiY.. A phase III comparison of standard radiation therapy (RT) versus split-course RT plus concurrent cisplatin (DDP) versus RT plus concurrent DDP and 5-fluorouracil in patients with unresectable squamous cell head and neck cancer (SCHNC): an intergroup study.Proc Annu Meet Am Soc Clin Oncol.2000; 19: 1624. Abstract.
24.
StaarS., RudatV., StuetzerH.. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicenter randomized German trial in advanced head-and-neck cancer.Int J Radiat Oncol Biol Phys.2001; 50: 1161–1171.
25.
Induction chemotherapy plus radiation compared with surgery plus radiation with advanced laryngeal cancer.The Department of Veterans Affairs Laryngeal Cancer Study Group.N Engl J Med.1991; 324: 1685–1690.
26.
ForastiereA.A., BerkeyB., MaorM.. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 4. Abstract.
MouldR.F., TaiT.H.. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.Br J Radiol.2002; 75: 307–339.
29.
RossiA., MolinariR., BoracchiP.. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study.J Clin Oncol.1988; 6: 1401–1410.
30.
ChiK.H., ChangY.C., GuoW.Y.. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients.Int J Radiat Oncol Biol Phys.2002; 52: 1238–1244.
31.
ChanA.T., TeoP.M., LeungT.W.. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.Int J Radiat Oncol Biol Phys.1995; 33: 560–577.
32.
CvitkovicE., GrangeG.R.L., le TempleS.. Neoadjuvant chemotherapy (NACT) with epirubicin (EPI) cisplatin (CDDP) bleomycin (BLEO) (BEC) in undifferentiated nasopharyngeal cancer (UCNT): preliminary results of an international phase III trial.Proc Annu Meet Am Soc Clin Oncol.1994; 13: 283.
33.
International Nasopharynx Cancer Study Group.Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatinum, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progress-free survival.Int J Radiat Oncol Biol Phys.1996; 35: 463–469.
34.
ChauD.T., ShamJ.S., ChoyD.. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma.Cancer.1998; 83: 2270–2283.
35.
Al-SarrafM., LeBlancM., GiriP.G.S.. Superiority of five year survival with chemoradiotherapy (CT-RT) vs radiotherapy in patients (pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 905. Abstract.
36.
Al-SarrafM., LeBlancM., GiriP.G.S.. Chemo radiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.J Clin Oncol.1998; 16: 1310–1317.
37.
MaJ., MaiH.Q., HongM.H.. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.J Clin Oncol.2001; 19: 1350–1357.
38.
HareyamamM., SakataK, ShiratoH.. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.Cancer.2002; 94: 2217–2223.
39.
ChanA.T.C., TeoP.M.L., NganR.K.. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.J Clin Oncol.2002; 20: 2038–2044.
40.
HoJ.H.. Stage classification of nasopharyngeal carcinoma: a review.IARC Sci Publ.1978; 20: 99–113.
41.
HuncharekM., KupelnickB.. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials.Am J Clin Oncol.2002; 25: 219–223.
42.
RischinD., PetersL., CorryJ.. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation.J Clin Oncol.2002; 20: 1845–1852.
43.
HongW.K., ArquetteM., NabellL.. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 895. Abstract.
44.
KiesM.S., ClaymanG.L., El-NaggarA.K.. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 225a.
45.
CohenE.E.W., RosenF., DekkerA.. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).Proc Annu Meet Am Soc Clin Oncol.2002; 21: 899. Abstract.
46.
BaselgaS., TrigoJ.M., BourhisJ.. Cetuximab (C225) plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 900. Abstract.
47.
BurtnessB.A., LiY., FloodW.. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC).Proc Annu Meet Am Soc Clin Oncol.2002; 21: 901. Abstract.
48.
ZahalskyA.J., WongR.J., LisE.. Phase II trial of SU5416 in patients with advanced incurable head and neck cancer.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 902. Abstract.
49.
SenzerN.N., SoulieresD., SiuL.. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 6. Abstract.
50.
RobertF., EzekielM.P., SpencerS.A.. Phase I study of anti-epidermoid factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.J Clin Oncol.2001; 19: 3234–3243.
51.
KimE.S., KiesM., HerbstR.S.. Novel therapeutics for head and neck cancer.Curr Opin Oncol.2002; 14: 334–342.
52.
HerbstR.S., LangerC.J.. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.Semin Oncol.2002; 29(suppl 4): 27–36.
